Mesotelioma

National Comprehensive Cancer Network. NCCN clinical practice guidelines in oncology: mesothelioma: pleural [internet publication].Texto completo

Woolhouse I, Bishop L, Darlison L, et al. British Thoracic Society guideline for the investigation and management of malignant pleural mesothelioma. Thorax. 2018 Mar;73(suppl 1):i1-30.Texto completo  Resumo

Popat S, Baas P, Faivre-Finn C, et al. Malignant pleural mesothelioma: ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2022 Feb;33(2):129-42.Texto completo  Resumo

Kindler HL, Ismaila N, Armato SG 3rd, et al. Treatment of malignant pleural mesothelioma: American Society of Clinical Oncology clinical practice guideline. J Clin Oncol. 2018 May 1;36(13):1343-73.Texto completo  Resumo

1. Carbone M, Ly BH, Dodson RF, et al. Malignant mesothelioma: facts, myths, and hypotheses. J Cell Physiol. 2012 Jan;227(1):44-58.Texto completo  Resumo

2. National Comprehensive Cancer Network. NCCN clinical practice guidelines in oncology: mesothelioma: pleural [internet publication].Texto completo

3. Larson T, Melnikova N, Davis SI, et al. Incidence and descriptive epidemiology of mesothelioma in the United States, 1999-2002. Int J Occup Environ Health. 2007 Oct-Dec;13(4):398-403. Resumo

4. Centers for Disease Control and Prevention (CDC). Malignant mesothelioma mortality - United States, 1999-2005. MMWR Morb Mortal Wkly Rep. 2009 Apr 24;58(15):393-6.Texto completo  Resumo

5. Price B, Ware A. Mesothelioma trends in the United States: an update based on Surveillance, Epidemiology, and End Results Program data for 1973 through 2003. Am J Epidemiol. 2004 Jan 15;159(2):107-12.Texto completo  Resumo

6. Henley SJ, Larson TC, Wu M, et al. Mesothelioma incidence in 50 states and the District of Columbia, United States, 2003-2008. Int J Occup Environ Health. 2013 Jan-Mar;19(1):1-10. Resumo

7. National Cancer Institute Surveillance, Epidemiology, and End Results Program. Mesothelioma: recent trends in SEER age-adjusted incidence rates, 2000-2020. Observed SEER incidence rate by sex, all races/ethnicities, all ages, all stages. SEER*Explorer: an interactive website for SEER cancer statistics. Jun 2023 [internet publication].Texto completo

8. Mazurek JM, Syamlal G, Wood JM, et al. Malignant mesothelioma mortality - United States, 1999-2015. MMWR Morb Mortal Wkly Rep. 2017 Mar 3;66(8):214-8.Texto completo  Resumo

9. Nishikawa K, Takahashi K, Karjalainen A, et al. Recent mortality from pleural mesothelioma, historical patterns of asbestos use, and adoption of bans: a global assessment. Environ Health Perspect. 2008 Dec;116(12):1675-80.Texto completo  Resumo

10. Cugell DW, Kamp DW. Asbestos and the pleura: a review. Chest. 2004 Mar;125(3):1103-17. Resumo

11. Mossman BT, Kamp DW, Weitzman SA. Mechanisms of carcinogenesis and clinical features of asbestos-associated cancers. Cancer Invest. 1996;14(5):466-80. Resumo

12. Roggli VL, Sharma A, Butnor KJ, et al. Malignant mesothelioma and occupational exposure to asbestos: a clinicopathological correlation of 1445 cases. Ultrastruct Pathol. 2002 Mar-Apr;26(2):55-65. Resumo

13. Gulati M, Redlich CA. Asbestosis and environmental causes of usual interstitial pneumonia. Curr Opin Pulm Med. 2015 Mar;21(2):193-200.Texto completo  Resumo

14. GBD 2013 Mortality and Causes of Death Collaborators. Global, regional, and national age-sex specific all-cause and cause-specific mortality for 240 causes of death, 1990-2013: a systematic analysis for the Global Burden of Disease Study 2013. Lancet. 2015 Jan 10;385(9963):117-71.Texto completo  Resumo

15. Carbone M, Yang H, Pass HI, et al. BAP1 and cancer. Nat Rev Cancer. 2013 Mar;13(3):153-9.Texto completo  Resumo

16. Goodman JE, Nascarella MA, Valberg PA. Ionizing radiation: a risk factor for mesothelioma. Cancer Causes Control. 2009 Oct;20(8):1237-54. Resumo

17. Roushdy-Hammady I, Siegel J, Emri S, et al. Genetic-susceptibility factor and malignant mesothelioma in the Cappadocian region of Turkey. Lancet. 2001 Feb 10;357(9254):444-5. Resumo

18. Rivera Z, Strianese O, Bertino P, et al. The relationship between simian virus 40 and mesothelioma. Curr Opin Pulm Med. 2008 Jul;14(4):316-21. Resumo

19. Testa JR, Cheung M, Pei J, et al. Germline BAP1 mutations predispose to malignant mesothelioma. Nat Genet. 2011 Aug 28;43(10):1022-5.Texto completo  Resumo

20. Bott M, Brevet M, Taylor BS, et al. The nuclear deubiquitinase BAP1 is commonly inactivated by somatic mutations and 3p21.1 losses in malignant pleural mesothelioma. Nat Genet. 2011 Jun 5;43(7):668-72.Texto completo  Resumo

21. Peterson JT Jr, Greenberg SD, Buffler PA. Non-asbestos-related malignant mesothelioma. A review. Cancer. 1984 Sep 1;54(5):951-60. Resumo

22. Toyokuni S. Iron overload as a major targetable pathogenesis of asbestos-induced mesothelial carcinogenesis. Redox Rep. 2014 Jan;19(1):1-7. Resumo

23. Kamp DW. Asbestos-induced lung diseases: an update. Transl Res. 2009 Apr;153(4):143-52. Resumo

24. Guo G, Chmielecki J, Goparaju C, et al. Whole-exome sequencing reveals frequent genetic alterations in BAP1, NF2, CDKN2A, and CUL1 in malignant pleural mesothelioma. Cancer Res. 2015 Jan 15;75(2):264-9.Texto completo  Resumo

25. Harington JS, Wagner JC, Smith M. The detection of hyaluronic acid in pleural fluids of cases with diffuse pleural mesotheliomas. Br J Exp Pathol. 1963 Feb;44:81-3. Resumo

26. Wagner JC. The discovery of the association between blue asbestos and mesotheliomas and the aftermath. Br J Ind Med. 1991 Jun;48(6):399-403.Texto completo  Resumo

27. Hodgson JT, Darnton A. The quantitative risks of mesothelioma and lung cancer in relation to asbestos exposure. Ann Occup Hyg. 2000 Dec;44(8):565-601.Texto completo  Resumo

28. National Cancer Institute Surveillance, Epidemiology, and End Results Program. Mesothelioma: recent trends in SEER age-adjusted incidence rates, 2000-2020. Observed SEER incidence rate by sex, all races/ethnicities, ages 65+, all stages. SEER*Explorer: an interactive website for SEER cancer statistics. Jun 2023 [internet publication].Texto completo

29. Olsen NJ, Franklin PJ, Reid A, et al. Increasing incidence of malignant mesothelioma after exposure to asbestos during home maintenance and renovation. Med J Aust. 2011 Sep 5;195(5):271-4.Texto completo  Resumo

30. Chirieac LR, Barletta JA, Yeap BY, et al. Clinicopathologic characteristics of malignant mesotheliomas arising in patients with a history of radiation for Hodgkin and non-Hodgkin lymphoma. J Clin Oncol. 2013 Dec 20;31(36):4544-9.Texto completo  Resumo

31. Neri M, Ugolini D, Boccia S, et al. Chemoprevention of asbestos-linked cancers: a systematic review. Anticancer Res. 2012 Mar;32(3):1005-13. Resumo

32. US Preventive Services Task Force. Vitamin, mineral, and multivitamin supplementation to prevent cardiovascular disease and cancer: preventive medication. Jun 2022 [internet publication].Texto completo

33. Omenn GS, Goodman GE, Thornquist MD, et al. Effects of a combination of beta carotene and vitamin A on lung cancer and cardiovascular disease. N Engl J Med. 1996 May 2;334(18):1150-5.Texto completo  Resumo

34. Alpha-Tocopherol, Beta Carotene Cancer Prevention Study Group. The effect of vitamin E and beta carotene on the incidence of lung cancer and other cancers in male smokers. N Engl J Med. 1994 Apr 14;330(15):1029-35.Texto completo  Resumo

35. Woolhouse I, Bishop L, Darlison L, et al. British Thoracic Society guideline for the investigation and management of malignant pleural mesothelioma. Thorax. 2018 Mar;73(suppl 1):i1-30.Texto completo  Resumo

36. Popat S, Baas P, Faivre-Finn C, et al. Malignant pleural mesothelioma: ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2022 Feb;33(2):129-42.Texto completo  Resumo

37. National Institute for Health and Care Excellence. Suspected cancer: recognition and referral. Oct 2023 [internet publication].Texto completo

38. Kindler HL, Ismaila N, Armato SG 3rd, et al. Treatment of malignant pleural mesothelioma: American Society of Clinical Oncology clinical practice guideline. J Clin Oncol. 2018 May 1;36(13):1343-73.Texto completo  Resumo

39. Leung AN, Müller NL, Miller RR. CT in differential diagnosis of diffuse pleural disease. AJR Am J Roentgenol. 1990 Mar;154(3):487-92.Texto completo  Resumo

40. Renshaw AA, Dean BR, Antman KH, et al. The role of cytologic evaluation of pleural fluid in the diagnosis of malignant mesothelioma. Chest. 1997 Jan;111(1):106-9. Resumo

41. Muers MF, Stephens RJ, Fisher P, et al. Active symptom control with or without chemotherapy in the treatment of patients with malignant pleural mesothelioma (MS01): a multicentre randomised trial. Lancet. 2008 May 17;371(9625):1685-94.Texto completo  Resumo

42. Boutin C, Rey F. Thoracoscopy in pleural malignant mesothelioma: a prospective study of 188 consecutive patients. Part 1: Diagnosis. Cancer. 1993 Jul 15;72(2):389-93. Resumo

43. Wang ZJ, Reddy GP, Gotway MB, et al. Malignant pleural mesothelioma: evaluation with CT, MR imaging, and PET. Radiographics. 2004 Jan-Feb;24(1):105-19.Texto completo  Resumo

44. de Perrot M, Feld R, Cho BC, et al. Trimodality therapy with induction chemotherapy followed by extrapleural pneumonectomy and adjuvant high-dose hemithoracic radiation for malignant pleural mesothelioma. J Clin Oncol. 2009 Mar 20;27(9):1413-8. Resumo

45. US Food & Drug Administration. Fujirebio Mesomark assay​. Humanitarian device exemption (HDE). H060004. Jan 2007 [internet publication].Texto completo

46. Zhu M, Lu Z, Guo H, et al. Diagnostic value of combination of biomarkers for malignant pleural mesothelioma: a systematic review and meta-analysis. Front Oncol. 2023;13:1136049.Texto completo  Resumo

47. Lu Z, Zhang W, Huang K, et al. Systematic review, meta-analysis and bioinformatic analysis of biomarkers for prognosis of malignant pleural mesothelioma. Diagnostics (Basel). 2022 Sep 12;12(9):2210.Texto completo  Resumo

48. Schillebeeckx E, van Meerbeeck JP, Lamote K. Clinical utility of diagnostic biomarkers in malignant pleural mesothelioma: a systematic review and meta-analysis. Eur Respir Rev. 2021 Nov 17;30(162):210057.Texto completo  Resumo

49. Cagle PT, Churg A. Differential diagnosis of benign and malignant mesothelial proliferations on pleural biopsies. Arch Pathol Lab Med. 2005 Nov;129(11):1421-7. Resumo

50. American Thoracic Society. Diagnosis and initial management of nonmalignant diseases related to asbestos. Am J Respir Crit Care Med. 2004 Sep 15;170(6):691-715.Texto completo  Resumo

51. Rusch VW. A proposed new international TNM staging system for malignant pleural mesothelioma. From the International Mesothelioma Interest Group. Chest. 1995 Oct;108(4):1122-8. Resumo

52. Edge SB, Greene FL, Byrd DR, et al., eds. AJCC cancer staging manual. 8th ed. New York, NY: Springer; 2017.

53. Blum TG, Morgan RL, Durieux V, et al. European Respiratory Society guideline on various aspects of quality in lung cancer care. Eur Respir J. 2023 Feb 16;61(2):2103201.Texto completo  Resumo

54. National Cancer Institute Surveillance, Epidemiology, and End Results Program. All cancer sites combined: recent trends in SEER age-adjusted incidence rates, 2000-2020. By sex, delay-adjusted SEER incidence rate, all races/ethnicities, all ages. SEER*Explorer: an interactive website for SEER cancer statistics. Jun 2023 [internet publication].Texto completo

55. Alnajar A, Kareff SA, Razi SS, et al. Disparities in survival due to social determinants of health and access to treatment in US patients with operable malignant pleural mesothelioma. JAMA Netw Open. 2023 Mar 1;6(3):e234261.Texto completo  Resumo

56. Rusch VW, Piantadosi S, Holmes EC. The role of extrapleural pneumonectomy in malignant pleural mesothelioma. A Lung Cancer Study Group trial. J Thorac Cardiovasc Surg. 1991 Jul;102(1):1-9. Resumo

57. Zellos L, Jaklitsch MT, Al-Mourgi MA, et al. Complications of extrapleural pneumonectomy. Semin Thorac Cardiovasc Surg. 2007 Winter;19(4):355-9. Resumo

58. Flores RM, Pass HI, Seshan VE, et al. Extrapleural pneumonectomy versus pleurectomy/decortication in the surgical management of malignant pleural mesothelioma: results in 663 patients. J Thorac Cardiovasc Surg. 2008 Mar;135(3):620-6, 626.e1-3. Resumo

59. Treasure T, Lang-Lazdunski L, Waller D, et al. Extra-pleural pneumonectomy versus no extra-pleural pneumonectomy for patients with malignant pleural mesothelioma: clinical outcomes of the Mesothelioma and Radical Surgery (MARS) randomised feasibility study. Lancet Oncol. 2011 Aug;12(8):763-72.Texto completo  Resumo

60. Krug LM, Pass HI, Rusch VW, et al. Multicenter phase II trial of neoadjuvant pemetrexed plus cisplatin followed by extrapleural pneumonectomy and radiation for malignant pleural mesothelioma. J Clin Oncol. 2009 Jun 20;27(18):3007-13. Resumo

61. Flores RM, Krug LM, Rosenzweig KE, et al. Induction chemotherapy, extrapleural pneumonectomy, and postoperative high-dose radiotherapy for locally advanced malignant pleural mesothelioma: a phase II trial. J Thorac Oncol. 2006 May;1(4):289-95. Resumo

62. Weder W, Stahel RA, Bernhard J, et al; Swiss Group for Clinical Cancer Research. Multicenter trial of neo-adjuvant chemotherapy followed by extrapleural pneumonectomy in malignant pleural mesothelioma. Ann Oncol. 2007 Jul;18(7):1196-202.Texto completo  Resumo

63. Green J, Dundar Y, Dodd S, et al. Pemetrexed disodium in combination with cisplatin versus other cytotoxic agents or supportive care for the treatment of malignant pleural mesothelioma. Cochrane Database Syst Rev. 2007 Jan 24;(1):CD005574.Texto completo  Resumo

64. Ceresoli GL, Zucali PA, Favaretto AG, et al. Phase II study of pemetrexed plus carboplatin in malignant pleural mesothelioma. J Clin Oncol. 2006 Mar 20;24(9):1443-8.Texto completo  Resumo

65. Zalcman G, Mazieres J, Margery J, et al; French Cooperative Thoracic Intergroup (IFCT). Bevacizumab for newly diagnosed pleural mesothelioma in the Mesothelioma Avastin Cisplatin Pemetrexed Study (MAPS): a randomised, controlled, open-label, phase 3 trial. Lancet. 2016 Apr 2;387(10026):1405-14. Resumo

66. Baas P, Scherpereel A, Nowak AK, et al. First-line nivolumab plus ipilimumab in unresectable malignant pleural mesothelioma (CheckMate 743): a multicentre, randomised, open-label, phase 3 trial. Lancet. 2021 Jan 30;397(10272):375-386. Resumo

67. Waliany S, Lee D, Witteles RM, et al. Immune checkpoint inhibitor cardiotoxicity: understanding basic mechanisms and clinical characteristics and finding a cure. Annu Rev Pharmacol Toxicol. 2021 Jan 6;61:113-34.Texto completo  Resumo

68. Wu L, Tsang V, Menzies AM, et al. Risk factors and characteristics of checkpoint inhibitor-associated autoimmune diabetes mellitus (CIADM): a systematic review and delineation from type 1 diabetes. Diabetes Care. 2023 Jun 1;46(6):1292-9.Texto completo  Resumo

69. Fennell DA, Steele JP, Shamash J, et al. Efficacy and safety of first- or second-line irinotecan, cisplatin, and mitomycin in mesothelioma. Cancer. 2007 Jan 1;109(1):93-9. Resumo

70. Stebbing J, Powles T, McPherson K, et al. The efficacy and safety of weekly vinorelbine in relapsed malignant pleural mesothelioma. Lung Cancer. 2009 Jan;63(1):94-7. Resumo

71. Zucali PA, Ceresoli GL, Garassino I, et al. Gemcitabine and vinorelbine in pemetrexed-pretreated patients with malignant pleural mesothelioma. Cancer. 2008 Apr 1;112(7):1555-61. Resumo

72. Pinto C, Zucali PA, Pagano M, et al. Gemcitabine with or without ramucirumab as second-line treatment for malignant pleural mesothelioma (RAMES): a randomised, double-blind, placebo-controlled, phase 2 trial. Lancet Oncol. 2021 Oct;22(10):1438-47. Resumo

73. Rice DC, Stevens CW, Correa AM, et al. Outcomes after extrapleural pneumonectomy and intensity-modulated radiation therapy for malignant pleural mesothelioma. Ann Thorac Surg. 2007 Nov;84(5):1685-92. Resumo

74. Allen AM, Czerminska M, Janne PA, et al. Fatal pneumonitis associated with intensity-modulated radiation therapy for mesothelioma. Int J Radiat Oncol Biol Phys. 2006 Jul 1;65(3):640-5. Resumo

75. Stahel RA, Riesterer O, Xyrafas A, et al. Neoadjuvant chemotherapy and extrapleural pneumonectomy of malignant pleural mesothelioma with or without hemithoracic radiotherapy (SAKK 17/04): a randomised, international, multicentre phase 2 trial. Lancet Oncol. 2015 Dec;16(16):1651-8. Resumo

76. Gupta V, Mychalczak B, Krug L, et al. Hemithoracic radiation therapy after pleurectomy/decortication for malignant pleural mesothelioma. Int J Radiat Oncol Biol Phys. 2005 Nov 15;63(4):1045-52. Resumo

77. Lee TT, Everett DL, Shu HK, et al. Radical pleurectomy/decortication and intraoperative radiotherapy followed by conformal radiation with or without chemotherapy for malignant pleural mesothelioma. J Thorac Cardiovasc Surg. 2002 Dec;124(6):1183-9. Resumo

78. Rimner A, Zauderer MG, Gomez DR, et al. Phase II study of hemithoracic intensity-modulated pleural radiation therapy (IMPRINT) as part of lung-sparing multimodality therapy in patients with malignant pleural mesothelioma. J Clin Oncol. 2016 Aug 10;34(23):2761-8. Resumo

79. Patel R, Ludmir EB, Miccio JA, et al. Disease-related outcomes and toxicities of intensity modulated radiation therapy after lung-sparing pleurectomy for malignant pleural mesothelioma: a systematic review. Pract Radiat Oncol. 2020 Nov-Dec;10(6):423-33. Resumo

80. Boutin C, Rey F, Viallat JR. Prevention of malignant seeding after invasive diagnostic procedures in patients with pleural mesothelioma. A randomized trial of local radiotherapy. Chest. 1995 Sep;108(3):754-8. Resumo

81. Bydder S, Phillips M, Joseph DJ, et al. A randomised trial of single-dose radiotherapy to prevent procedure tract metastasis by malignant mesothelioma. Br J Cancer. 2004 Jul 5;91(1):9-10.Texto completo  Resumo

82. O'Rourke N, Garcia JC, Paul J, et al. A randomised controlled trial of intervention site radiotherapy in malignant pleural mesothelioma. Radiother Oncol. 2007 Jul;84(1):18-22. Resumo

83. Nagendran M, Pallis A, Patel K, et al. Should all patients who have mesothelioma diagnosed by video-assisted thoracoscopic surgery have their intervention sites irradiated? Interact Cardiovasc Thorac Surg. 2011 Jul;13(1):66-9.Texto completo  Resumo

84. Clive AO, Taylor H, Dobson L, et al. Prophylactic radiotherapy for the prevention of procedure-tract metastases after surgical and large-bore pleural procedures in malignant pleural mesothelioma (SMART): a multicentre, open-label, phase 3, randomised controlled trial. Lancet Oncol. 2016 Aug;17(8):1094-104.Texto completo  Resumo

85. Muruganandan S, Azzopardi M, Fitzgerald DB, et al. Aggressive versus symptom-guided drainage of malignant pleural effusion via indwelling pleural catheters (AMPLE-2): an open-label randomised trial. Lancet Respir Med. 2018 Sep;6(9):671-80. Resumo

86. Clive AO, Jones HE, Bhatnagar R, et al. Interventions for the management of malignant pleural effusions: a network meta-analysis. Cochrane Database Syst Rev. 2016 May 8;(5):CD010529.Texto completo  Resumo

87. Rintoul RC, Ritchie AJ, Edwards JG, et al.; MesoVATS Collaborators. Efficacy and cost of video-assisted thoracoscopic partial pleurectomy versus talc pleurodesis in patients with malignant pleural mesothelioma (MesoVATS): an open-label, randomised, controlled trial. Lancet. 2014 Sep 20;384(9948):1118-27. Resumo

88. Rueda JR, Solà I, Pascual A, et al. Non-invasive interventions for improving well-being and quality of life in patients with lung cancer. Cochrane Database Syst Rev. 2011 Sep 7;(9):CD004282.Texto completo  Resumo

89. Hui D, Bohlke K, Bao T, et al. Management of dyspnea in advanced cancer: ASCO Guideline. J Clin Oncol. 2021 Apr 20;39(12):1389-411.Texto completo  Resumo

90. Brims F, Gunatilake S, Lawrie I, et al. Early specialist palliative care on quality of life for malignant pleural mesothelioma: a randomised controlled trial. Thorax. 2019 Apr;74(4):354-61.Texto completo  Resumo

91. Popat S, Curioni-Fontecedro A, Dafni U, et al. A multicentre randomised phase III trial comparing pembrolizumab versus single-agent chemotherapy for advanced pre-treated malignant pleural mesothelioma: the European Thoracic Oncology Platform (ETOP 9-15) PROMISE-meso trial. Ann Oncol. 2020 Dec;31(12):1734-45.Texto completo  Resumo

92. Chu Q, Perrone F, Greillier L, et al. Pembrolizumab plus chemotherapy versus chemotherapy in untreated advanced pleural mesothelioma in Canada, Italy, and France: a phase 3, open-label, randomised controlled trial. Lancet. 2023 Dec 16;402(10419):2295-306. Resumo

93. Zagiel B, Melnyk P, Cotelle P. Progress with YAP/TAZ-TEAD inhibitors: a patent review (2018-present). Expert Opin Ther Pat. 2022 Aug;32(8):899-912.Texto completo  Resumo

94. Cunningham R, Hansen CG. The Hippo pathway in cancer: YAP/TAZ and TEAD as therapeutic targets in cancer. Clin Sci (Lond). 2022 Feb 11;136(3):197-222.Texto completo  Resumo

95. ClinicalTrials.gov. Oral TEAD inhibitor targeting the Hippo pathway in subjects with advanced solid tumors​. NCT05228015. Jul 2023 [internet publication].Texto completo

96. Amidon BS, Sanchez-Martin M, Bartolini W, et al. Abstract 2156: IK-930 is a novel TEAD inhibitor for the treatment of cancers harboring mutations in the Hippo signal transduction pathway. Proceedings of the American Association for Cancer Research Annual Meeting 2022. Cancer Res. 2022;82(suppl 12):abstract nr 2156.Texto completo

97. Häuser W, Welsch P, Radbruch L, et al. Cannabis-based medicines and medical cannabis for adults with cancer pain. Cochrane Database Syst Rev. 2023 Jun 5;6(6):CD014915. Resumo

98. Kristensen CA, Nottrup TJ, Berthelsen AK, et al. Pulmonary toxicity following IMRT after extrapleural pneumonectomy for malignant pleural mesothelioma. Radiother Oncol. 2009 Jul;92(1):96-9. Resumo

99. Rice DC, Smythe WR, Liao Z, et al. Dose-dependent pulmonary toxicity after postoperative intensity-modulated radiotherapy for malignant pleural mesothelioma. Int J Radiat Oncol Biol Phys. 2007 Oct 1;69(2):350-7. Resumo

100. Vogelzang NJ, Rusthoven JJ, Symanowski J, et al. Phase III study of pemetrexed in combination with cisplatin versus cisplatin alone in patients with malignant pleural mesothelioma. J Clin Oncol. 2003 Jul 15;21(14):2636-44. Resumo

101. Ligibel JA, Bohlke K, May AM, et al. Exercise, diet, and weight management during cancer treatment: ASCO guideline. J Clin Oncol. 2022 Aug 1;40(22):2491-507.Texto completo  Resumo

102. Roeland EJ, Bohlke K, Baracos VE, et al. Cancer cachexia: ASCO guideline rapid recommendation update. J Clin Oncol. 2023 Sep 1;41(25):4178-9.Texto completo  Resumo

103. Carlson LE, Ismaila N, Addington EL, et al. Integrative oncology care of symptoms of anxiety and depression in adults with cancer: Society for Integrative Oncology-ASCO guideline. J Clin Oncol. 2023 Oct 1;41(28):4562-91.Texto completo  Resumo